An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

Brand Name Drug

A drug marketed under a proprietary, protected name, typically developed by a single pharmaceutical company and often protected by patents.

Government-granted Exclusivities

Legal protections, such as patents or data exclusivity, granted by the government to drug manufacturers that prevent other companies from making or selling a generic version of a drug for a certain period.

Non-exclusive License

A permission granted to multiple entities to use, make, or sell a patented product or technology, meaning the original rights holder can grant similar licenses to others, and does not restrict competition among licensees.

Generic Drug

A copy of a brand-name drug that has the same active ingredient, dosage form, safety, strength, route of administration, quality, and performance characteristics as the original, but is typically sold at a much lower price after the original drug's patent expires.

Biosimilar Biological Product

A biological product that is highly similar to an already approved biological product (reference product), with no clinically meaningful differences in terms of safety, purity, and potency.

Reasonable Royalty

A payment made by a licensee to a patent holder for the right to use their patented invention, typically a percentage of sales or a fixed amount, determined to be fair under the circumstances.